Your browser doesn't support javascript.
loading
Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia.
Shih, Alan H; Meydan, Cem; Shank, Kaitlyn; Garrett-Bakelman, Francine E; Ward, Patrick S; Intlekofer, Andrew M; Nazir, Abbas; Stein, Eytan M; Knapp, Kristina; Glass, Jacob; Travins, Jeremy; Straley, Kim; Gliser, Camelia; Mason, Christopher E; Yen, Katharine; Thompson, Craig B; Melnick, Ari; Levine, Ross L.
Afiliação
  • Shih AH; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Meydan C; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Shank K; Department of Medicine/Hematology-Oncology and Department of Pharmacology, Weill Cornell Medical College, New York, New York.
  • Garrett-Bakelman FE; Department of Physiology and Biophysics and the HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medical College, New York, New York.
  • Ward PS; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Intlekofer AM; Department of Medicine/Hematology-Oncology and Department of Pharmacology, Weill Cornell Medical College, New York, New York.
  • Nazir A; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Stein EM; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Knapp K; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Glass J; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Travins J; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Straley K; Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Gliser C; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Mason CE; Department of Medicine/Hematology-Oncology and Department of Pharmacology, Weill Cornell Medical College, New York, New York.
  • Yen K; Agios Pharmaceuticals, Cambridge, Massachusetts.
  • Thompson CB; Agios Pharmaceuticals, Cambridge, Massachusetts.
  • Melnick A; Agios Pharmaceuticals, Cambridge, Massachusetts.
  • Levine RL; Department of Physiology and Biophysics and the HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medical College, New York, New York.
Cancer Discov ; 7(5): 494-505, 2017 05.
Article em En | MEDLINE | ID: mdl-28193779
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas Proto-Oncogênicas / Proteínas de Ligação a DNA / Terapia de Alvo Molecular / Isocitrato Desidrogenase Limite: Animals Idioma: En Revista: Cancer Discov Ano de publicação: 2017 Tipo de documento: Article País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas Proto-Oncogênicas / Proteínas de Ligação a DNA / Terapia de Alvo Molecular / Isocitrato Desidrogenase Limite: Animals Idioma: En Revista: Cancer Discov Ano de publicação: 2017 Tipo de documento: Article País de publicação: Estados Unidos